Cause-specific mortality in lean individuals with metabolic dysfunction-associated steatotic liver disease

Le résumé fourni par la source

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) can occur in both nonlean and lean individuals. This study aimed to compare the risk of cause-specific mortality between lean and nonlean MASLD patients and investigate the impact of advanced fibrosis on mortality. METHOD: This population-based cohort study included 14,740 adults from the National Health and Nutrition Examination Survey (NHANES). The NAFLD Fibrosis Score (NFS) or Fibrosis-4 score (FIB-4) was employed to identify advanced fibrosis. Cox proportional hazard models were utilized to analyze all-cause mortality, whereas competing risk models were applied to analyze cause-specific mortality. RESULTS: During a median follow-up of 7.3 (4.1–10.7) years, lean MASLD patients presented increased risks for all-cause mortality (HR = 2.50, 95% CI = 1.70–3.66) and diabetes-specific mortality (sHR = 5.00, 95% CI = 1.40–17.8) compared with nonlean MASLD patients. No significant differences were observed in cardiovascular-specific or cancer-specific mortality risk between the two groups. Stratified analyses revealed a significant interaction effect between lean MASLD and advanced fibrosis on all-cause mortality risk. Among lean MASLD patients with advanced fibrosis, the incidence rates per 1,000 person-years were 110.6 (95% CI = 58.5-185.2) for all-cause mortality, 27.7 (5.7–78.7) for cardiovascular-specific mortality, 9.2 (0.2–50.3) for cancer-specific mortality and 9.2 (0.2–50.3) for diabetes-specific mortality. An FIB-4 score > 2.67 and NFS > 0.676 could indicate an increased risk of all-cause mortality in lean MASLD patients, with no significant difference in performance. CONCLUSION: Lean MASLD patients had greater risks of all-cause and diabetes-specific mortality than nonlean MASLD patients, and regular noninvasive fibrosis evaluation is recommended for lean MASLD patients.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.